Muscarinic agonists for the treatment of cognition in schizophrenia

Angela K. Sellin, Mujeeb Shad, Carol Tamminga

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

It is widely accepted that cholinergic activity at muscarinic receptors is required to maintain cognitive functions, including learning and memory. Memory domains are especially impaired in schizophrenia, which may explain difficulties in psychosocial rehabilitation of individuals with this illness. However, little is known about the mechanism of this impairment. To understand our current knowledge, we reviewed the literature since 1990 via a PubMed search for the terms "muscarinic", "schizophrenia", "cognition", "memory", "learning", and "agonist" in combination. We found 89 basic science/laboratory studies, case reports/series, case-control studies, cross-sectional studies, standardized controlled animal trials, standardized controlled human trials, and reviews. Although further research is required to fully understand the neuropharmacology of the cholinergic system in cognitive function in schizophrenia, we have examined the data currently available. In general, these data suggest that agonist activity at acetylcholine muscarinic type 1 (M1) receptors would enhance memory and learning in schizophrenia. We present an overview of likely side effects of muscarinic agonists. We outline the anticholinergic activity of several available antipsychotics and review the available M1 muscarinic agonists.

Original languageEnglish (US)
Pages (from-to)985-996
Number of pages12
JournalCNS Spectrums
Volume13
Issue number11
StatePublished - 2008

Fingerprint

Muscarinic Agonists
Cognition
Cholinergic Agents
Schizophrenia
Learning
Muscarinic Receptors
Neuropharmacology
Cholinergic Antagonists
Therapeutics
PubMed
Antipsychotic Agents
Case-Control Studies
Cross-Sectional Studies
Research

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Muscarinic agonists for the treatment of cognition in schizophrenia. / Sellin, Angela K.; Shad, Mujeeb; Tamminga, Carol.

In: CNS Spectrums, Vol. 13, No. 11, 2008, p. 985-996.

Research output: Contribution to journalArticle

Sellin, Angela K. ; Shad, Mujeeb ; Tamminga, Carol. / Muscarinic agonists for the treatment of cognition in schizophrenia. In: CNS Spectrums. 2008 ; Vol. 13, No. 11. pp. 985-996.
@article{1a8991fa444f48a097207543a3e6798b,
title = "Muscarinic agonists for the treatment of cognition in schizophrenia",
abstract = "It is widely accepted that cholinergic activity at muscarinic receptors is required to maintain cognitive functions, including learning and memory. Memory domains are especially impaired in schizophrenia, which may explain difficulties in psychosocial rehabilitation of individuals with this illness. However, little is known about the mechanism of this impairment. To understand our current knowledge, we reviewed the literature since 1990 via a PubMed search for the terms {"}muscarinic{"}, {"}schizophrenia{"}, {"}cognition{"}, {"}memory{"}, {"}learning{"}, and {"}agonist{"} in combination. We found 89 basic science/laboratory studies, case reports/series, case-control studies, cross-sectional studies, standardized controlled animal trials, standardized controlled human trials, and reviews. Although further research is required to fully understand the neuropharmacology of the cholinergic system in cognitive function in schizophrenia, we have examined the data currently available. In general, these data suggest that agonist activity at acetylcholine muscarinic type 1 (M1) receptors would enhance memory and learning in schizophrenia. We present an overview of likely side effects of muscarinic agonists. We outline the anticholinergic activity of several available antipsychotics and review the available M1 muscarinic agonists.",
author = "Sellin, {Angela K.} and Mujeeb Shad and Carol Tamminga",
year = "2008",
language = "English (US)",
volume = "13",
pages = "985--996",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "11",

}

TY - JOUR

T1 - Muscarinic agonists for the treatment of cognition in schizophrenia

AU - Sellin, Angela K.

AU - Shad, Mujeeb

AU - Tamminga, Carol

PY - 2008

Y1 - 2008

N2 - It is widely accepted that cholinergic activity at muscarinic receptors is required to maintain cognitive functions, including learning and memory. Memory domains are especially impaired in schizophrenia, which may explain difficulties in psychosocial rehabilitation of individuals with this illness. However, little is known about the mechanism of this impairment. To understand our current knowledge, we reviewed the literature since 1990 via a PubMed search for the terms "muscarinic", "schizophrenia", "cognition", "memory", "learning", and "agonist" in combination. We found 89 basic science/laboratory studies, case reports/series, case-control studies, cross-sectional studies, standardized controlled animal trials, standardized controlled human trials, and reviews. Although further research is required to fully understand the neuropharmacology of the cholinergic system in cognitive function in schizophrenia, we have examined the data currently available. In general, these data suggest that agonist activity at acetylcholine muscarinic type 1 (M1) receptors would enhance memory and learning in schizophrenia. We present an overview of likely side effects of muscarinic agonists. We outline the anticholinergic activity of several available antipsychotics and review the available M1 muscarinic agonists.

AB - It is widely accepted that cholinergic activity at muscarinic receptors is required to maintain cognitive functions, including learning and memory. Memory domains are especially impaired in schizophrenia, which may explain difficulties in psychosocial rehabilitation of individuals with this illness. However, little is known about the mechanism of this impairment. To understand our current knowledge, we reviewed the literature since 1990 via a PubMed search for the terms "muscarinic", "schizophrenia", "cognition", "memory", "learning", and "agonist" in combination. We found 89 basic science/laboratory studies, case reports/series, case-control studies, cross-sectional studies, standardized controlled animal trials, standardized controlled human trials, and reviews. Although further research is required to fully understand the neuropharmacology of the cholinergic system in cognitive function in schizophrenia, we have examined the data currently available. In general, these data suggest that agonist activity at acetylcholine muscarinic type 1 (M1) receptors would enhance memory and learning in schizophrenia. We present an overview of likely side effects of muscarinic agonists. We outline the anticholinergic activity of several available antipsychotics and review the available M1 muscarinic agonists.

UR - http://www.scopus.com/inward/record.url?scp=60249093377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60249093377&partnerID=8YFLogxK

M3 - Article

C2 - 19037177

AN - SCOPUS:60249093377

VL - 13

SP - 985

EP - 996

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 11

ER -